Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on therapy with omega-3 fatty acids in adolescents at high risk of psychosis
2008-005004-13Phase 3Completed
- Sponsor
- Orygen Research Centre
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Schizophrenia Spectrum Disorders (SSD), schizophrenia and Clinical high risk for psychosis (CHR) comparing Omega-3 fatty acids add-on with Placebo add-on (2 arms). Primary endpoint: Transition to first episode of psychosis. Started Oct 2010; status: completed.
02
Drugs
omega-3 fatty acids + eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophreniaClinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on 2008-005004-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005004-13.